Target (CBDY) Free Cash Flow (2013 - 2026)
Target (CBDY) reported Free Cash Flow of -$133720.0 for Q1 2026, up 76.54% year-over-year from -$75746.3 in Q1 2025, and up 46.67% quarter-over-quarter from -$250739.0 in Q4 2025.
Target (CBDY) Free Cash Flow (2013 - 2026) Analysis & Trends
Target (CBDY) has 14 years of Free Cash Flow data on file, last reported at -$133720.0 in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$133720.0, up 76.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$480860.0 (down 164.0% YoY), and the FY2025 annual result was -$917052.0, down 143.81% from the prior year.
- Free Cash Flow grew to -$133720.0 in Q1 2026 per CBDY's latest filing, from -$250739.0 in the prior quarter.
- Over five years, Free Cash Flow peaked at $960643.0 in Q2 2024 and troughed at -$1.4 million in Q3 2023.
- A 5-year average of $40620.5 and a median of $55381.0 in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow slumped 1160.18% in 2023, then jumped 513.33% in 2024.
- A 5-year view of Free Cash Flow shows it stood at $55381.0 in 2022, then surged by 392.85% to $272945.0 in 2023, then soared by 167.35% to $729712.0 in 2024, then tumbled by 134.36% to -$250739.0 in 2025, then soared by 46.67% to -$133720.0 in 2026.
- Business Quant data shows CBDY's Free Cash Flow at -$133720.0 in Q1 2026, -$250739.0 in Q4 2025, and -$553641.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -208.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 291.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 362.50 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 136.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -38.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -169.83 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 80.53 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 123.09 Mn |
| 10 | Target | - | - | 191,787.00 | -133,720.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -133,720.00 |
| Mar 31, 2026 | -133,720.00 |
| Dec 31, 2025 | -250,739.00 |
| Dec 31, 2025 | -250,739.00 |
| Sep 30, 2025 | -553,641.00 |
| Sep 30, 2025 | -553,641.00 |
| Jun 30, 2025 | 457,240.00 |
| Jun 30, 2025 | 457,240.00 |
| Mar 31, 2025 | -569,912.00 |
| Mar 31, 2025 | -569,912.00 |
| Dec 31, 2024 | 729,712.00 |
| Dec 31, 2024 | 729,712.00 |
| Sep 30, 2024 | -369,046.00 |
| Sep 30, 2024 | -369,046.00 |
| Jun 30, 2024 | 960,643.00 |
| Jun 30, 2024 | 960,643.00 |
| Mar 31, 2024 | 771,931.00 |
| Mar 31, 2024 | 771,931.00 |
| Dec 31, 2023 | 272,945.00 |
| Dec 31, 2023 | 272,945.00 |